Phase 1

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Alkermes) ALK4230-A101 / ARTISTRYA Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsHirte, Dr HalRecruitment on hold - COVID-19NCT02799095
(BI) 1381.1 / REFMAL 473An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours Hirte, Dr HalRecruitment on hold - COVID-19NCT02952248
(BMS) CA209848 / CheckMate 848A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or
Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High
Tumor Mutational Burden (TMB-H)
Hotte, Dr SebastienRecruitment on hold - COVID-19NCT03668119
(Esperas) ESPS-001A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic CancerHirte, Dr HalRecruitment on hold - COVID-19NCT02632448
(Fusion) FPX-01-01A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid TumoursJuergens, Dr RosalynRecruitment on hold - COVID-19NCT03746431
(Pfizer) B9991040A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Bempegaldesleukin (NKTR-214) with or without Talazoparib or Enzalutamide in Participants with Locally Advanced or Metastatic Solid TumorsHotte, Dr SebastienRecruitment on hold - COVID-19NCT04052204
(SignalChem) SLC-391-101A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study of the Safety and Pharmacokinetics of the AXL Inhibitor SLC-391 Administered Orally to Subjects with Solid TumoursHotte, Dr SebastienRecruitment on hold - COVID-19NCT03990454
Download PDF